Helen Torley, Halozyme CEO
In bid to remake itself after pancreatic cancer flop, Halozyme acquires Antares and its drug delivery tech for $960M
After the market hibernated for much of the first quarter, things are starting to get moving as the calendar turns toward Q2. And following the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
